Health Technology · Pharmaceuticals: Major · NSE: ANURAS · data 2026-10-09
Anupam Rasayan India Ltd.
Health check: Weak (3.9/10 on quality, valuation vs sector, growth and momentum).
Open full analysis — chart, results, balance sheet, red flags →Key figures
Price
₹1,132.4
Market cap
₹12,459 cr
P/E
73.6
P/B
—
ROE
5.5%
ROCE
9.0%
Debt / equity
0.57
Dividend yield
0.14%
1-year return
2.0%
52-week high
₹1,415
52-week low
₹1,047.9
Operating margin
15.7%
Growth
| Revenue (last 12 months) | ₹2,535 cr |
| Net profit (last 12 months) | ₹175 cr |
| Sales growth, 3 years (yearly) | 14.1% |
| Profit growth, 3 years (yearly) | -2.0% |
Similar companies
Jubilant Pharmova Limited (JUBLPHARMA) · AstraZeneca Pharma India Limited (ASTRAZEN) · Indegene Limited (INDGN) · Marksans Pharma Limited (MARKSANS) · Corona Remedies Limited (CORONA)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open ANURAS in NSE Scanner →